Search Result
Results for "
replicons
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
15
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N6798
-
Myriocin
Maximum Cited Publications
11 Publications Verification
Thermozymocidin; ISP-I
|
HCV
Antibiotic
|
Infection
|
|
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection .
|
-
-
- HY-15602
-
|
GS-5885
|
HCV
SARS-CoV
|
Infection
|
|
Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
|
-
-
- HY-W063968
-
|
CDM-3008; RO4948191
|
IFNAR
JAK
STAT
HCV
HBV
|
Infection
|
|
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .
|
-
-
- HY-10237
-
|
EBP 520; SCH 503034
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
|
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
-
- HY-12530
-
|
GS-5816
|
HCV
SARS-CoV
|
Infection
Inflammation/Immunology
Cancer
|
|
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
-
- HY-10466
-
Daclatasvir
Maximum Cited Publications
47 Publications Verification
BMS-790052; EBP 883
|
HCV
|
Infection
|
|
Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
|
-
-
- HY-10468
-
NM107
1 Publications Verification
2'-C-Methylcytidine
|
HCV
|
Infection
|
|
NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM .
|
-
-
- HY-13998
-
|
ABT-333
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
|
-
-
- HY-10465
-
|
BMS-790052 dihydrochloride; EBP 883 dihydrochloride
|
HCV
|
Infection
|
|
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
|
-
-
- HY-109035
-
|
SB9200; GS-9992
|
HCV
HBV
|
Infection
|
|
Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant HCV variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .
|
-
-
- HY-125371
-
|
|
HCV
|
Infection
Inflammation/Immunology
|
|
2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication. 2'-C-Methyladenosine inhibits HCV replicon and NS5B-catalyzed RNA synthesis with IC50 values of 0.3μM and 1.9 μM, respectively. 2'-C-Methyladenosine also potently inhibits LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis .
|
-
-
- HY-101662
-
|
ABT-530
|
HCV
|
Infection
|
|
Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
|
-
-
- HY-15602B
-
|
GS-5885 D-tartrate
|
HCV
|
Infection
|
|
Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
|
-
-
- HY-15602A
-
|
GS-5885 (acetone)
|
HCV
|
Infection
|
|
Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
|
-
-
- HY-15236
-
|
RO 2433; GS-331007
|
HCV
|
Infection
|
|
PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.
|
-
-
- HY-75800
-
|
VX-222
|
DNA/RNA Synthesis
HCV
|
Infection
|
|
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .
|
-
-
- HY-10244
-
MK-0608
1 Publications Verification
|
HCV
|
Infection
|
|
MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay .
|
-
-
- HY-15005S1
-
|
PSI-7977-d6; GS-7977-d6
|
Isotope-Labeled Compounds
HCV
|
Infection
|
|
Sofosbuvir-d6 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
-
- HY-135867E
-
|
|
CHIKV
Endogenous Metabolite
Enterovirus
HCV
Topoisomerase
SARS-CoV
|
Infection
|
|
NHC-triphosphate tetraammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetraammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .
|
-
-
- HY-146344
-
|
|
DNA/RNA Synthesis
|
Infection
|
|
Antiviral agent 17 is an anti-infection agent. Antiviral agent 17 retains its antiviral effect in a human replicon assay (EC50 = 0.015 μM). Antiviral agent 17 results in good antiviral activity against murine norovirus with an EC50 of 7 nM. . Antiviral agent 17 has the potential for the research of infectious and malignant diseases .
|
-
-
- HY-124191
-
|
PPI-668 hydrochloride
|
HCV
|
Infection
|
|
Ravidasvir hydrochloride (PPI-668 hydrochloride) is a pan-genotypic inhibitor for hepatitis C virus (HCV) NS5A protein. Ravidasvir hydrochloride inhibits the replication of HCV, with EC50 of 0.12, 0.01 and 1.14 nM, for HCV gt-1a, gt-1b, and gt-3a replicons, respectively. Ravidasvir hydrochloride exhibits good pharmacokinetic characters in rats .
|
-
-
- HY-W540972
-
|
Primuline
|
Fluorescent Dye
HCV
Dengue Virus
|
Infection
|
|
Primulin is a versatile fluorescent dye and bioactive compound widely used in analytical, biological, botanical and virological studies. Primulin acts as a versatile stain that labels plant cell walls and differentiates live and dead spermatozoa via distinct fluorescence patterns. Primulin exhibits strong albumin‑binding capacity. Primulin acts as a retrograde axonal tracer in neurobiological investigations. Primulin and its derivatives inhibit HCV NS3, block dengue virus NS3-mediated ATP hydrolysis, and disrupt HCV replicase assembly .
|
-
-
- HY-10444
-
R-1479
3 Publications Verification
4'-Azidocytidine
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
-
- HY-10118
-
|
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .
|
-
-
- HY-N0620
-
|
|
HCV
|
Infection
|
|
Mulberroside C is one of the main bioactive constituents in mulberry (Morus alba L.) . Mulberroside C is a HCV replicon inhibitor. Antiviral activity .
|
-
-
- HY-136797
-
|
|
Dengue Virus
|
Infection
|
|
BP13944 is a potential small molecule inhibitor discovered by high-throughput screening. It can effectively inhibit the expression of dengue virus (DENV) replicons with an EC50 value of 1.03±0.09 μM. BP13944 can inhibit the replication or viral RNA synthesis of all four serotypes of DENV, but is ineffective against Japanese encephalitis virus. BP13944 may target the DENV NS3 protease, and the E66G amino acid substitution in the NS3 protease region will cause the virus to become resistant to BP13944. BP13944 has no obvious cytotoxicity. As there is currently no effective dengue vaccine and treatment, BP13944, as an effective small molecule inhibitor, may become a potential agent for the treatment of dengue in the future.
|
-
-
- HY-13465
-
VCH-916
1 Publications Verification
|
HCV
|
Infection
|
|
VCH-916 is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase with sub-micromolar IC50 values versus genotype 1a and 1b replicons. VCH-916 binds to Thumb Site II. VCH-916 can be used for the research of hepatitis c virus (hcv) infection .
|
-
-
- HY-16784
-
|
IDX719; IDX18719
|
HCV
HCV Protease
|
Infection
|
|
Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons .
|
-
-
- HY-138305
-
-
-
- HY-10465R
-
|
BMS-790052 dihydrochloride (Standard); EBP 883 dihydrochloride (Standard)
|
Reference Standards
HCV
|
Infection
|
|
Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
|
-
-
- HY-135867
-
-
-
- HY-15602C
-
|
GS-5885 hydrochloride
|
HCV
SARS-CoV
|
Infection
|
|
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
|
-
-
- HY-12530R
-
|
GS-5816 (Standard)
|
Reference Standards
HCV
SARS-CoV
|
Infection
Inflammation/Immunology
Cancer
|
|
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
-
- HY-N8188
-
|
|
HCV
HCV Protease
|
Infection
|
|
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35?μM) .
|
-
-
- HY-15602D
-
|
GS-5885 (diacetone)
|
HCV
|
Infection
|
|
Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
|
-
-
- HY-15005A
-
|
|
HCV
|
Infection
|
|
PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
-
- HY-135867A
-
|
|
CHIKV
Endogenous Metabolite
Enterovirus
HCV
Topoisomerase
|
Infection
|
|
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .
|
-
-
- HY-15602AS
-
|
GS-5885-d6 hydrochloride
|
HCV
Isotope-Labeled Compounds
|
Infection
|
|
Ledipasvir-d6 hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
|
-
-
- HY-14391
-
|
GS-558093
|
HCV
|
Infection
|
|
PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes .
|
-
-
- HY-112047
-
|
GSK2878175
|
HCV
|
Infection
|
|
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .
|
-
-
- HY-131905S
-
|
|
Isotope-Labeled Compounds
HCV Protease
HCV
|
Infection
Inflammation/Immunology
Cancer
|
|
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
|
-
-
- HY-U00213
-
|
R803
|
HCV
|
Infection
|
|
Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC50, ~30 nM) than against the genotype 2a replicon (EC50, ~1,000 nM).
|
-
-
- HY-111087
-
-
-
- HY-15005B
-
|
|
Drug Metabolite
|
Others
|
|
Sofosbuvir impurity C is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
-
- HY-15005S
-
|
PSI-7977-13C,d3; GS-7977-13C,d3
|
Isotope-Labeled Compounds
HCV
|
Infection
|
|
Sofosbuvir- 13C,d3 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
-
- HY-135867F
-
|
|
CHIKV
Endogenous Metabolite
Enterovirus
HCV
Topoisomerase
SARS-CoV
|
Infection
|
|
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA .
|
-
-
- HY-12633
-
|
|
HCV
|
Inflammation/Immunology
|
|
GS-6620 is potent and selective HCV inhibitor. GS-6620 inhibits HCV replication in genotype 1-6 subgenomic replicons and genotype 2a infectious virus, with EC50 values of 0.048-0.68 μM. GS-6620 can be used for the researches of infection and inflammation, such as Hepatitis C Virus (HCV) .
|
-
-
- HY-15602S
-
|
GS-5885-d6
|
HCV
SARS-CoV
|
Infection
|
|
Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM .
|
-
-
- HY-13998A
-
|
ABT-333 sodium
|
HCV
DNA/RNA Synthesis
|
Infection
|
|
Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
|
-
-
- HY-102030
-
|
|
HCV
|
Infection
|
|
BMS-961955 is an orally active inhibitor of HCV NS5B polymerase. BMS-961955 exhibits potent inhibitory activity against HCV genotype 1 (GT-1a/1b) replicons with EC50s of 4.3 nM and 7.9 nM, respectively. BMS-961955 can be used for the study of HCV infection .
|
-
- HY-10237R
-
|
EBP 520 (Standard); SCH 503034 (Standard)
|
Reference Standards
HCV Protease
HCV
SARS-CoV
|
Infection
|
|
Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
|
-
- HY-15236S
-
|
RO-2433-13C,d3; GS-331007-13C,d3; Sofosbuvir metabolite GS-331007-13C,d3
|
HCV
|
Infection
|
|
PSI-6206- 13C,d3 is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.
|
-
- HY-12530S1
-
|
GS-5816-d33
|
Isotope-Labeled Compounds
SARS-CoV
HCV
|
Infection
Inflammation/Immunology
Cancer
|
|
Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
- HY-114571
-
|
cis-VX-222
|
DNA/RNA Synthesis
HCV
|
Infection
|
|
cis-Lomibuvir (cis-VX-222) is the cis-isomer of Lomibuvir. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis . cis-Lomibuvir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-75800R
-
|
VX-222 (Standard)
|
DNA/RNA Synthesis
HCV
Reference Standards
|
Infection
|
|
Lomibuvir (Standard) is the analytical standard of Lomibuvir. This product is intended for research and analytical applications. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .
|
-
- HY-10466R
-
|
BMS-790052 (Standard); EBP 883 (Standard)
|
Reference Standards
HCV
|
Infection
|
|
Daclatasvir (Standard) is the analytical standard of Daclatasvir. This product is intended for research and analytical applications. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
|
-
- HY-162924
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs .
|
-
- HY-I0723
-
|
|
Drug Metabolite
|
Others
|
|
Sofosbuvir impurity D is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
- HY-I0719
-
|
|
Drug Metabolite
|
Others
|
|
Sofosbuvir impurity B is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
- HY-I0727
-
|
|
Drug Metabolite
|
Others
|
|
Sofosbuvir impurity E is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
- HY-136267
-
|
|
HCV
|
Infection
|
|
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .
|
-
- HY-12732
-
|
|
HCV
|
Infection
|
|
PTC 725 is a potent, selective and orally active Hepatitis C Virus NS4B Protein inhibitor. PTC 725 inhibits HCV 1b (Con1) replicons .
|
-
- HY-157405
-
|
|
Dengue Virus
|
Infection
|
|
DENV-IN-11 (SC27), a sulfonamide chalcone, is a potent DENV inhibitor that targeted viral methyltransferase. DENV-IN-11 reduced DENV2 replicon replication. DENV-IN-11 can be used for dengue infection research .
|
-
- HY-12373
-
|
|
HCV Protease
Influenza Virus
|
Infection
|
|
AV-4025 hydrochloride (Compound 13a) is an orally active NS5A inhibitor. AV-4025 hydrochloride is active against the HCV replicon GT1b (EC50 = 0.003 nM). AV-4025 hydrochloride can be used for research on hepatitis C infection .
|
-
- HY-147763
-
|
|
HCV
|
Infection
|
|
HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons .
|
-
- HY-147764
-
|
|
HCV
|
Infection
|
|
HCV-IN-40 (Compound 18c) is a potent, orally active hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.259, 0.434 and 0.069 μM against GT1a, GT1b and GT1b CES1 replicons .
|
-
- HY-19921
-
|
|
HCV
|
Infection
|
|
JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.
|
-
- HY-10468R
-
|
2'-C-Methylcytidine (Standard)
|
Reference Standards
HCV
|
Infection
|
|
NM107 (Standard) is the analytical standard of NM107. This product is intended for research and analytical applications. NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM .
|
-
- HY-10237S
-
|
EBP 520-d9; SCH 503034-d9
|
Isotope-Labeled Compounds
HCV Protease
HCV
SARS-CoV
|
Infection
|
|
Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
- HY-168564
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CL pro with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-27 exhibits excellent anti-SARS-CoV-2 replicon activity, demonstrating an EC50 value of 5 nM .
|
-
- HY-15602S1
-
|
GS-5885-d16
|
Isotope-Labeled Compounds
HCV
SARS-CoV
|
Infection
|
|
Ledipasvir-d16 (GS-5885-d16) is deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
|
-
- HY-177299
-
|
|
HCV
|
Infection
|
|
HCV NS5B polymerase-IN-3 (Compound 30a) is an inhibitor of the HCV NS5B polymerase. HCV NS5B polymerase-IN-3 exhibits anti-HCV activity in the Huh7 replicon cell line with an EC50 of 0.23 μM and shows no obvious cytotoxicity. HCV NS5B polymerase-IN-3 can be used in research related to the hepatitis C virus .
|
-
- HY-13998R
-
|
ABT-333 (Standard)
|
Reference Standards
HCV
DNA/RNA Synthesis
|
Infection
|
|
Dasabuvir (Standard) is the analytical standard of Dasabuvir. This product is intended for research and analytical applications. Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
|
-
- HY-10466S
-
|
BMS-790052-d6; EBP 883-d6
|
Isotope-Labeled Compounds
HCV
|
Infection
|
|
Daclatasvir-d6 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
|
-
- HY-146344R
-
|
|
Reference Standards
DNA/RNA Synthesis
|
Infection
|
|
Antiviral agent 17 (Standard) is the analytical standard of Antiviral agent 17 (HY-146344). This product is intended for research and analytical applications. Antiviral agent 17 is an anti-infection agent. Antiviral agent 17 retains its antiviral effect in a human replicon assay (EC50 = 0.015 μM). Antiviral agent 17 results in good antiviral activity against murine norovirus with an EC50 of 7 nM. . Antiviral agent 17 has the potential for the research of infectious and malignant diseases .
|
-
- HY-10466S2
-
|
BMS-790052-d16; EBP 883-d16
|
Isotope-Labeled Compounds
HCV
|
Infection
|
|
Daclatasvir-d16 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
|
-
- HY-W749691
-
|
(S)-GS-5816-13C,d3
|
Isotope-Labeled Compounds
SARS-CoV
HCV
|
Infection
Inflammation/Immunology
Cancer
|
|
(S)-Velpatasvir- 13C,d3 ((S)-GS-5816- 13C,d3) is 13C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
- HY-N6798R
-
|
Thermozymocidin (Standard); ISP-I (Standard)
|
Reference Standards
HCV
Antibiotic
|
Infection
|
|
Myriocin (Standard) is the analytical standard of Myriocin. This product is intended for research and analytical applications. Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection[1][2][3].
|
-
- HY-12530S3
-
|
GS-5816-13C,d3
|
Isotope-Labeled Compounds
|
Infection
Inflammation/Immunology
Cancer
|
|
Velpatasvir- 13C,d3 (GS-5816- 13C,d3) is 13C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
- HY-15236S1
-
|
RO 2433--d1,13C,15N2; GS-331007--d1,13C,15N2
|
HCV
Isotope-Labeled Compounds
|
Infection
|
|
PSI-6206-d1, 13C, 15N2 is 15N and 13C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.
|
-
- HY-125182
-
|
|
Cyclophilin
HCV
|
Infection
|
|
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .
|
-
- HY-10466S1
-
|
BMS-790052-13C2,d6; EBP 883-13C2,d6
|
Isotope-Labeled Compounds
HCV
|
Infection
|
|
Daclatasvir- 13C2,d6 (BMS-790052- 13C2,d6) is 13C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
|
-
- HY-128306
-
|
|
HCV Protease
DNA/RNA Synthesis
|
Infection
|
|
HCV-IN-50 (Compound 2) is a competitive and selective HCV NS5B RNA-dependent RNA polymerase inhibitor with an IC50 of 0.3 μM for NS5B △C21 enzyme over △C55 enzyme. HCV-IN-50 has an antiviral activity and efficiently blocks replication of HCV subgenomic replicons especially mutant replicons .
|
-
- HY-108029
-
|
ACH-2684 sodium; Neceprevir sodium
|
HCV
HCV Protease
|
Infection
|
|
Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .
|
-
- HY-117802
-
|
|
DNA/RNA Synthesis
HCV
HCV Protease
|
Infection
|
|
CID-50930756 is an HCV NS3 helicase inhibitor with an IC50 of 22 μM.CID-50930756 inhibits HCV NS3 helicase-catalyzed nucleic acid unwinding.CID-50930756 inhibits HCV replication in hepatoma cells harboring a stably transfected subgenomic HCV replicon.CID-50930756 does not exhibit toxicity to hepatoma cells at 10 μM.CID-50930756 shows weak DNA-binding activity, displacing less than 20% of SYBR Green I from DNA at 100 μM.CID-50930756 can be used for the research of hepatitis c .
|
-
- HY-182691
-
|
|
HCV
|
Infection
|
|
Amphihevir is an orally active HCV NS4B inhibitor. Amphihevir exhibits activity against HCV genotype 1a and 1b replicons and reduces HCV RNA levels. Amphihevir can be used in the research of chronic hepatitis C .
|
-
- HY-114216
-
|
|
Endogenous Metabolite
|
Infection
|
|
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .
|
-
- HY-10244R
-
|
|
Reference Standards
HCV
|
Infection
|
|
MK-0608 (Standard) is the analytical standard of MK-0608 (HY-10244). This product is intended for research and analytical applications. MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay .
|
-
- HY-17677
-
|
|
Influenza Virus
SARS-CoV
|
Infection
|
|
Antiviral agent 78 (Compound 27) is an antiviral agent. Antiviral agent 78 shows IC50 values of 11.22, 78.54 and 71.49 μM against 2019-nCoV, Ebola virus replicon and avian influenza virus A/Guangzhou/99. Antiviral agent 78 can be used for research of virus infection .
|
-
- HY-123536
-
|
A-831
|
PI4K
HCV
|
Infection
|
|
AZD2836 (A-831) is a 4-aminopyrazolone compound with anti-HCV activity. AZD2836 inhibits the activity of the host cell kinase PI4KIIIα, causing metabolic disorder of the cell membrane component PI4P that is necessary for viral replication. In the HCV subgenomic replicon cell model, the EC50 values of AZD2836 for genotype 1b (Con1 strain) and genotype 1a (Lemon strain) are 270 nM and 550 nM, respectively .
|
-
- HY-182603
-
|
|
Drug Derivative
Reactive Oxygen Species (ROS)
HCV
|
Infection
Inflammation/Immunology
|
|
BO-653 is an orally active anti-atherosclerotic antioxidant that exhibits high binding affinity for LDL. BO-653 scavenges linoleic acid peroxyl radicals, inhibits lipid peroxidation during the auto-oxidation of linoleic acid, and potently suppresses LDL oxidation. BO-653 inhibits Hepatitis C Virus (HCV) replication in a concentration-dependent manner, with an IC50 of 36.0 μM against the HCV subgenomic replicon in FLR3-1 cells. BO-653 demonstrates significant anti-atherosclerotic effects in various animal models, including the Watanabe heritable hyperlipidemic rabbit. BO-653 is suitable for use in research related to atherosclerosis and Hepatitis C Virus infection .
|
-
- HY-10444R
-
|
4'-Azidocytidine (Standard)
|
Reference Standards
HCV
DNA/RNA Synthesis
|
Infection
|
|
R-1479 (Standard) is the analytical standard of R-1479 (HY-10444). This product is intended for research and analytical applications. R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-182679
-
|
|
HCV
|
Infection
|
|
L0909 is an HCV inhibitor with an EC50 of 0.022 μM. L0909 blocks HCV replication by inhibiting E1-mediated viral entry. L0909 exhibits sensitivity to clinical resistant HCV mutants. L0909 displays synergistic effects with clinical HCV drugs. L0909 can be used for the research of hepatitis c virus (HCV) infection .
|
-
- HY-181990
-
|
|
Virus Protease
Flavivirus
|
|
|
IRBM-Z-1 is a non-competitive inhibitor of Zika virus (ZIKV) NS2B-NS3 protease, with an IC50 of 1.8 μM. IRBM-Z-1 also exhibits inhibitory activity against the NS2B-NS3 proteases of T156I-mutated dengue virus 2 (DENV2) and West Nile virus (WNV), with IC50 values of 3.9 μM and 4.7 μM, respectively. IRBM-Z-1 inhibits ZIKV replication, attenuates virus-induced cytopathic effects. IRBM-Z-1 is applicable to research related to ZIKV infection .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W540972
-
|
Primuline
|
Biochemical Assay Reagents
|
|
Primulin is a versatile fluorescent dye and bioactive compound widely used in analytical, biological, botanical and virological studies. Primulin acts as a versatile stain that labels plant cell walls and differentiates live and dead spermatozoa via distinct fluorescence patterns. Primulin exhibits strong albumin‑binding capacity. Primulin acts as a retrograde axonal tracer in neurobiological investigations. Primulin and its derivatives inhibit HCV NS3, block dengue virus NS3-mediated ATP hydrolysis, and disrupt HCV replicase assembly .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-15005S1
-
1 Publications Verification
|
|
Sofosbuvir-d6 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
-
- HY-15602AS
-
|
|
|
Ledipasvir-d6 hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
|
-
-
- HY-131905S
-
|
|
|
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .
|
-
-
- HY-15005S
-
|
|
|
Sofosbuvir- 13C,d3 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
|
-
-
- HY-15602S
-
|
|
|
Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM .
|
-
-
- HY-15236S
-
|
|
|
PSI-6206- 13C,d3 is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.
|
-
-
- HY-12530S1
-
|
|
|
Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
-
- HY-10237S
-
|
|
|
Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .
|
-
-
- HY-15602S1
-
|
|
|
Ledipasvir-d16 (GS-5885-d16) is deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
|
-
-
- HY-10466S
-
|
|
|
Daclatasvir-d6 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
|
-
-
- HY-10466S2
-
|
|
|
Daclatasvir-d16 is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
|
-
-
- HY-W749691
-
|
|
|
(S)-Velpatasvir- 13C,d3 ((S)-GS-5816- 13C,d3) is 13C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
-
- HY-12530S3
-
|
|
|
Velpatasvir- 13C,d3 (GS-5816- 13C,d3) is 13C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
|
-
-
- HY-15236S1
-
|
|
|
PSI-6206-d1, 13C, 15N2 is 15N and 13C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.
|
-
-
- HY-10466S1
-
|
|
|
Daclatasvir- 13C2,d6 (BMS-790052- 13C2,d6) is 13C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-10444
-
R-1479
3 Publications Verification
4'-Azidocytidine
|
|
Azide
|
|
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-10444
-
R-1479
3 Publications Verification
4'-Azidocytidine
|
|
Nucleoside Analogs
Cytidine
|
|
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of HCV. R-1479 inhibits HCV replication in the HCV subgenomic replicon system (IC50=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: